New hope for hard-to-treat lung cancer: combo therapy enters human testing

NCT ID NCT06816992

First seen Apr 24, 2026 · Last updated May 14, 2026 · Updated 3 times

Summary

This early-phase study tests a new drug (ORIC-114) combined with an existing targeted therapy (amivantamab) in about 76 people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The goal is to find the safest dose and see if the combination can shrink tumors or slow cancer growth. Participants must have this specific mutation and may have had prior chemotherapy or be newly diagnosed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • Peter MacCallum Cancer Centre

    NOT_YET_RECRUITING

    Melbourne, Victoria, 03000, Australia

  • The Princess Margaret Hospital

    NOT_YET_RECRUITING

    Toronto, Ontario, M5G 1Z5, Canada

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.